Costs of remdesivir injection have been voluntarily curtailed by many drug firms on the intervention of the govt, Nationwide Pharmaceutical Pricing Authority (NPPA) claimed on Saturday.
Drug firms like Cadila Healthcare, Dr Reddy’s Laboratories and Cipla have slice the charges of their respective manufacturers of remdesivir injection (a hundred mg/vial). The antiviral drug is used in the therapy of Covid-19.
“Owing to the government’s intervention, the rate of #Remdesivir Injection is now diminished! I am grateful to pharmaceutical firms for becoming a member of fingers with the Authorities to battle from Covid-19 Pandemic,” Union Minister of State for Chemical substances and Fertilisers Mansukh L Mandaviya tweeted.
According to the aspects shared by the NPPA, Cadila Healthcare has diminished the rate of its REMDAC (Remdesivir a hundred mg) injection to Rs 899 from Rs two,800 previously. Similarly, Syngene International has slice the rate of its brand name RemWin to Rs two,450 from Rs three,950 previously.
Hyderabad-based Dr Reddy’s Laboratories has slice the rate of REDYX, which used to expense Rs 5,four hundred previously to Rs two,seven hundred now. Similarly, Cipla has reducedP of its CIPREMI brand name to Rs three,000 from Rs four,000 previously.
Mylan has also diminished the rate of its brand name from Rs four,800 to Rs three,four hundred. Similarly, Jubilant Generics has slice the rate of its remdesivir brand name to Rs three,four hundred from Rs four,seven hundred previously.
Hetero Healthcare has also slice the rate of its brand name COVIFOR from Rs 5,four hundred to Rs three,490 now.
(Only the headline and photo of this report may have been reworked by the Company Conventional team the relaxation of the information is automobile-created from a syndicated feed.)